The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | Highlights from ESMO WCGIC 2022
Jonathan Strickler, MD, Duke Cancer Institute, Durham, NC, discusses some of the highlights from the ESMO WCGIC 2022 congress, including potentially practice-changing data from the MOUNTAINEER study (NCT03043313). This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
Disclosures
Consultant or advisory role: Abbvie, Takeda, AstraZeneca, Bayer, GSK, Inivata, Mereo Biopharma, Natera, Pfizer, Pionyr Immunotherapeutics, Seagen, Silverback Therapeutics, Viatris, Zentalis Compensated: Yes
Research funding or contracted research: Amgen, Bayer, Erasca, Seagen, Daiichi-Sankyo, Gossamer Bio, AStar D3, Sanofi, Roche/ Genentech, Curegenix, Nektar, Abbvie, Silverback Therapeutics Compensated: No
